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Abstract: Observational studies suggest an adverse effect of maternal hypovitaminosis D during
pregnancy. However, intervention studies failed to show convincing benefit from vitamin D
supplementation during pregnancy. With analytical advances, vitamin D can now be measured in
ten forms—including as epimers—which were thought to be biologically inactive, but can critically
impair immunoassays. The aim of this commentary is to highlight the potential clinical and analytical
significance of vitamin D epimers in the interpretation of vitamin D roles in pregnancy. Epimers may
contribute a considerable proportion of total vitamin D—especially in the neonate—which renders
the majority of common assays questionable. Furthermore, epimers have been suggested to have
activity in laboratory studies, and evidence suggests that the fetus contributes significantly to
epimer production. Maternal epimer levels contribute significantly to predict neonate circulating
25-hydroxyvitamin D concentrations. In conclusion, the existence of various vitamin D forms
(such as epimers) has been established, and their clinical significance remains obscure. These results
underscore the need for accurate measurements to appraise vitamin D status, in order to understand
the current gap between observational and supplementation studies on the field.
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1. Introduction
In the past years, vitamin D has gained in clinical significance, since its presence has been
associated with multiple health outcomes, mostly with the maintenance of bone preservation across
the lifespan [1]. This significance is also highlighted by the fact that hypovitaminosis D has been
hypothesized to be involved in the pathogenesis of several diseases, although improvement in bone
outcomes remain the only confirmed health outcome [1,2]. Gradually, intervention studies have
been conducted, focusing on the potential beneficial effects of vitamin D supplementation on these
outcomes [3–7].
However, most of these studies failed to show a benefit from vitamin D supplementation during
pregnancy, in several outcomes, implying that there is a knowledge gap between observational and
supplementation studies on the field [8–10]. The enzymatic machinery of the cell, 25-hydroxyvitamin
D-1 α-hydroxylase, acts on its primary target—25-hydroxyvitamin D (25(OH)D)—to produce the
active form of vitamin D, the 1,25(OH)2D, which in turn interacts with the nuclear vitamin D receptor
(VDR) [2]. The above reaction is the main metabolic pathway of vitamin D, but there are also several
minor metabolic pathways on the road to the final and prevailing vitamin D metabolites. In this
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regard, vitamin D epimers result from the epimerization pathway of the plethora of metabolites of
vitamin D3 [11]. The biological role of those epimers has yet to be elucidated, as a result of their
potential impact on serum assays resulting in analytical and perhaps clinical issues of vitamin D
status interpretation and supplementation [8] in the general population [9]. Recently, new emerging
theories [8–10] highlight the need to further investigate the analytical and clinical significance of
epimers during pregnancy, since under specific conditions there is a potent correlation between those
compounds and the health status of an ongoing pregnancy, as well as foetal birth parameters or
potential adverse outcomes [12,13].
The aim of this commentary is to highlight the potential clinical and analytical significance of
vitamin D epimers in the interpretation of maternal vitamin D status. It will be based on results focused
on the physiological and pathophysiological aspects of the roles of the epimer forms during pregnancy,
in the context of the current gap between observational and supplementation studies on the field.
2. Physiological role of vitamin D epimers
2.1. Overview of Epimer Physiology: Non-Pregnant State
In order to become active, 25(OH)D requires hydroxylation that takes place mainly in the kidney.
This results in the conversion to the active form 1,25(OH)2D, or to 24R,25-dihydroxyvitaminD3,
the presumably inactive form [14]. Except for those primary metabolites of vitamin D, focus has
recently been brought on minor intermediates of the catabolic process of vitamin D.
1,25(OH)2D3 is subjected to enzymatic C-24/C-23 hydroxylation [15]. The C-24 oxidation pathway
leads to the conversion of 1,25(OH)2D3 into calcitroic acid, and the C-23 oxidation pathway leads to
the formation of 1,25(OH)2D3-26,23-lactone. Whereas this oxidation is significantly associated with
inactivation, epimerization has been linked to the retention of significant biological activity [14,15].
The products of epimerization are called epimers. The C-3 epimerization pathway of 1,25(OH)2D3
produces 3-epi-1,25(OH)2D3, and the two molecules only differ in the configuration of the hydroxyl
group at the 3 carbon position.
Likewise, 3-epi-25(OH)D3 was then identified as C-3 epimerized metabolites of 25(OH)D,
and 3-epi-24,25(OH)2D3 and 3-epi-24,25(OH)2D3-24-glucuronide were identified as C-3 epimerized
metabolites of 24,25(OH)2D3 [12–15]. After all, 25(OH)D3 is the most abundant vitamin D metabolite
in circulation, and 3-epi-25(OH)D3 is the most prevalent epimer of 25(OH)D [14,15]. Epimers need to
be separated during the measurement of true vitamin D status, because they can display compatible
chromatography with vitamin D metabolites [14–17].
There is adequate evidence that at least one epimer form of vitamin D is present in adult blood in
significant circulating concentrations, although a small number of studies demonstrate contradicting
evidence [18–21]. Reasons for this controversy are likely due to differences in high-throughput liquid
chromatography-tandem mass spectrometry (LC-MS/MS) techniques in the quantification of the
epimers between studies, as well as to the different study populations. The formation of the epimer has
been reported in several cell lines, suggesting that they can be formed endogenously [20], which was
further supported by tracking epimer levels in an additional study [19].
Considering the above information, and given the considerable growth in interest in the roles of
epimer forms of vitamin D in vivo [11,16], it is essential to selectively and accurately measure multiple
forms of vitamin D separately [15,16,18]. The development of rapid accurate assays with this capability
is certainly a tantalizing prospect. Within the past five years, a number of research laboratories
have developed or acquired the ability to conduct advanced LC-MS/MS analyses (high-throughput
liquid chromatography-tandem mass spectrometry), affording the capability to measure up to ten
analogues of vitamin D in a short (>10 min) run. This is a technique that combines the physical
separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of
mass spectrometry (MS). Using improved LC-MS/MS methods, the C-3 epimer of 25(OH)D was
measured at levels between 5 and 92 ng/mL in 22.2% of infants, contributing between 8.7% and
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61.1% to the total 25(OH)D [19]. Notably, the proportion of the C-3 epimer appeared to decline in the
first year post-partum. However, the same study failed to detect the C-3 epimer in either healthy adult
blood samples or in those with compromised liver function. With advances in assay methodology,
a subsequent study revealed that the C-3 epimer was detected in adult blood samples at levels between
0.5 and 2.5 ng/mL, which were between 2.6% and 16.7% of the 25(OH)D levels [20]. In addition,
in a large adult cohort, concentrations of the epimer were quantifiable (≥1.41 ng/mL) in 33.4% of
whites and 15.0% of blacks, and made up on average 3.23% and 2.25% of total D3 (epimer + 25(OH)D3)
concentrations, respectively [21]. Low concentrations of the D3 epimer were also present in adult serum,
and overall the epimer concentration was moderately correlated with the 25(OH)D3 concentration.
A later LC-MS/MS study reported the C-3 epimer ratio in 214 samples with a mean value of
1.5 ± 1.9 ng/mL (range 0.1–23.7 ng/mL), giving a ratio of C-3 epimer to 25(OH)D3 ranging from 0%
to 25.5% [22]. More recently, every sample in a large cohort (n = 1148) was shown to contain the C-3
epimer of 25(OH)D3, with a relative abundance (compared to the total 25(OH)D) ranging between
1.8% and 24.8% [23]. This study also found the C-3 epimer of 25(OH)D2 in 88 (7.7%) of the subjects in
Thailand. A further study (n = 1122) revealed that all samples except two had detectable C-epimer
of 23OHD3, and in the quantified samples (96.4%), the levels of epimer were at circa 4.5% of the
25(OH)D [24].
2.2. Biological Significance of Vitamin D Epimers
Although being supported by a limited number of studies, the physiological role of the epimers
has yet to be clarified. The C-3 epimer demonstrated compatible biochemical activity to the active
1,25(OH)2D3 form in cell culture for roles in coactivator peptide recruitment and induction of
expression of vitamin D target genes [14]—a phenomenon which implies potential pharmacological
roles of the epimer forms in vivo. In detail, Molnar et al. [14] reported significant biological
activity and similar biochemical properties of 1α,25(OH)2-3-epi-D3 compared to 1α, 25(OH)2D3
in primary human keratinocytes. In all experiments, highly comparable time courses of incubation of
1 α,25(OH)2D3 and C-3 epimer were recorded with 3-epimer exceeding 1 α,25(OH)2D3 concentration
after longer incubation.
Human keratinocytes could provide an ideal cellular model to investigate the anti-proliferative
actions of C-3 epimer, since it has been found in a high concentration in this tissue [14]. On that
basis, the dose-dependent anti-proliferative effects of 1 α,25(OH)2D3 and 1 α,25(OH)2-3-epiD3 using
3H-thymidine incorporation assay were evaluated. The half maximal inhibitory concentration (IC50)
values for 1 α,25(OH)2D3 and C-3 epimer were highly similar (41.4 and 66.1 nM, respectively) with no
significant statistical difference, indicating a similar anti-proliferative activity. Recently, exogenous C-3
epimer was as effective as 25(OH)D3 in supporting bone mineral accretion in both male and female
rats [25]. Therefore, the significance of epimers in the context of their possible cell-specific effects in
the placenta may provide further insights into vitamin D homeostasis during pregnancy [26].
3. Vitamin D Epimers during Pregnancy, Birth, and Early and Neonatal Period
Previous research has established the presence of the C-3 epimer at birth and its decrease in the
first year after birth [19,27]. In addition, a number of studies [8,28] have applied precise techniques in
order to analyze concentrations of multiple forms of vitamin D in pregnancy. Extending the analyses to
the maternal–neonate pair, similar levels of epimers of 25(OH)D2 and 25(OH)D3 were found in mother
(4.8 ± 7.8 ng/mL) and neonates (4.5 ± 4.7 ng/mL) which contributed approximately 25% of the total
circulating vitamin D [11]. Linear regression modelling was used to show which characteristics predict
levels of neonate 25(OH)D, and maternal levels of epimers contributed 11.9%, implying a potential role
of epimers of both maternal and neonatal vitamin D equilibrium. A later study in maternal–neonate
pairs reported similar levels of C-3 epimer for maternal and cord samples (2.4 vs. 2.2 ng/mL) with the
proportion of epimer of the total 25(OH)D as 6.5% in maternal and 10.5% in cord samples [28].
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In both studies, however, advanced LC-MS/MS analyses were used [11,28], allowing accurate
quantification of vitamin D isoforms, which in turn resulted in accurate determination of both maternal
and neonatal 25(OH)D concentrations in terms of vitamin D insufficiency or deficiency. Specifically,
24.7% and 22.2% of the measured vitamin D forms were for the epimer forms for mothers and neonates,
respectively [11]. The same cohort of maternal–neonatal dyads would exhibit higher proportional
classification of their vitamin D status if a different assay was used, not allowing the measurement of
multiple forms of vitamin D (including epimers) separately.
4. What Is the Role of Epimer Measurement in Defining Maternal Hypovitaminosis D?
4.1. Analytical Issues
LC-MS/MS is a powerful technique that has very high specificity, making it useful in the
discrimination between all forms of vitamin D [20,29].
Many clinical studies rely on immunoassay techniques—which are undergoing constant
development—for studies in the general population as well in infants/pregnancy, although the
utilization of these techniques in infants can be problematic [30]. Extended efforts for the development
of a precise immunoassay for 25(OH)D do exist [31], and it is feasible that these could result in
separating multiple metabolites, including epimers. Immunoassays generally do not detect the epimer
forms, since cross-reactivity is typically ~1% [15,22,28–30]. Results to date point to the need of the
widespread adoption of chromatography methods, where the analysis is evidenced by the retention
period on the chromatographic column and by measuring several fragmentation events using multiple
reaction monitoring [20]. This latter point is critical to deconvolute the roles of all ten forms of vitamin
D in pregnancy, in particular cases where vitamin D supplementation is warranted. However, it should
be noted that not all LC-MS/MS techniques separate or quantify the epimer forms, since without
adequate separation, it may coelute with 25(OH)D [20,29].
It should be noted that in order to distinguish the multiple bioactive vitamin D metabolites
(including epimers), stringent sample collection and processing procedures may be required,
although no such results are available. Moreover, there is a wide heterogeneity in reporting on
the sample collection procedures and processing from maternal versus foetal sera for vitamin D epimer
analyses by various studies to date [8–10,14].
4.2. Should Measurement of Epimer Concentration Affect Clinical Decisions?
Previous findings have suggested that the epimers are inactive, and they were identified under
this assumption [15,16,18]. However, even if epimers lack any direct pharmacological function, it is
feasible that they play an indirect role by acting as competitors for binding proteins, receptors, or even
for hydroxylases required to activate the pro-forms and thus regulating vitamin D homeostasis.
This issue has not been addressed in most observational or supplementation studies reported so far,
where immunoassays were used for the determination of vitamin D status.
Finally, there is a clear association of detected epimer concentrations with anthropometric and
biochemical measurement that must be further unveiled after studies conducted in infants. The C-3
epimer was quantified in 97% of samples (mean = 25.6 ng/mL, n = 155), contributing to 36% of serum
25(OH)D, and the level decreased over the first year [32]. The levels of C-3 epimer were unrelated
to gestational age, age after delivery, height, or weight, but a negative association was found with
bilirubin and C-reactive protein. There is a strong suspicion that the fetus–placenta is a source of
epimer production after the detection of epimers in maternal, cord, and fetus blood—a result occurring
due to the utilization of advanced assays.
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5. Conclusions
Although the existence of various vitamin D forms (such as epimers) has been established,
their clinical significance remains obscure. Furthermore, recent data show that at least one epimer form
has activity in vitro. With the development of more advanced assays, a thorough understanding of the
interplay among the various vitamin D forms can be achieved. Specific and accurate assays highlight
that a considerable proportion of vitamin D exists as epimers. Currently, separate measurement
of epimers, through advanced assays, could overcome significant analytical and clinical issues.
Specifically, in the daily clinical setting, separate measurement of epimers could provide a useful tool
for the accurate measurement of 25(OH)D during pregnancy, in order to explain some of the aspects of
the current gap between observational and supplementation studies on the field. Further studies are
required to establish additional in vivo roles of epimers on human pregnancy.
Conflicts of Interest: The authors report no conflict of interest.
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